- Home
- PHVS vs CAPL Comparison
PHVS vs CAPL Comparison
Compare PHVS & CAPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- CAPL
- Stock Information
- Founded
- PHVS 2015
- CAPL 1992
- Country
- PHVS Switzerland
- CAPL United States
- Employees
- PHVS N/A
- CAPL N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- CAPL Oil Refining/Marketing
- Sector
- PHVS Health Care
- CAPL Energy
- Exchange
- PHVS Nasdaq
- CAPL Nasdaq
- Market Cap
- PHVS 980.9M
- CAPL 788.6M
- IPO Year
- PHVS 2021
- CAPL 2012
- Fundamental
- Price
- PHVS $20.06
- CAPL $20.35
- Analyst Decision
- PHVS Buy
- CAPL
- Analyst Count
- PHVS 6
- CAPL 0
- Target Price
- PHVS $37.17
- CAPL N/A
- AVG Volume (30 Days)
- PHVS 216.0K
- CAPL 34.7K
- Earning Date
- PHVS 08-13-2025
- CAPL 08-06-2025
- Dividend Yield
- PHVS N/A
- CAPL 10.46%
- EPS Growth
- PHVS N/A
- CAPL 100.77
- EPS
- PHVS N/A
- CAPL 1.13
- Revenue
- PHVS N/A
- CAPL $3,522,840,000.00
- Revenue This Year
- PHVS N/A
- CAPL N/A
- Revenue Next Year
- PHVS N/A
- CAPL N/A
- P/E Ratio
- PHVS N/A
- CAPL $17.82
- Revenue Growth
- PHVS N/A
- CAPL N/A
- 52 Week Low
- PHVS $11.51
- CAPL $19.05
- 52 Week High
- PHVS $26.33
- CAPL $25.73
- Technical
- Relative Strength Index (RSI)
- PHVS 48.84
- CAPL 34.55
- Support Level
- PHVS $20.06
- CAPL $19.78
- Resistance Level
- PHVS $22.30
- CAPL $20.33
- Average True Range (ATR)
- PHVS 1.13
- CAPL 0.48
- MACD
- PHVS -0.23
- CAPL -0.17
- Stochastic Oscillator
- PHVS 22.84
- CAPL 12.90
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.